Related Experiment Video
Updated: Feb 13, 2026

Local Anesthetic Thoracoscopy for Undiagnosed Pleural Effusion
Published on: November 10, 2023
Optimizing intrapleural bevacizumab dosing in non-small-cell lung cancer-mediated malignant pleural effusion: less is
Dawei Chen1, Xinyu Song2,3, Yan Zhang1
1Department of Radiotherapy, Shandong Cancer Hospital Affiliated to Shandong University, Jinan 250117, Shandong, PR China.
Aim:
Intrapleural infusion of bevacizumab (BEV) is an emerging clinical treatment for malignant pleural effusion, but many details of usage need to be determined, especially for the effective dose.
Patients & Methods:
We performed a retrospective study of the records of malignant pleural effusion patients from non-small-cell lung cancer who underwent intrapleural infusion of BEV. According to the BEV dose commonly used in clinical, patients were allocated into either low-dose group or high-dose group.
Results:
A total of 71 patients were enrolled in this study. Administration with intrapleural BEV in low dose has less toxicity. For survival data, low- and high-dose groups have no difference.
Conclusion:
Lower rates of serious BEV-related toxicities and similar survival date are noted when lower dosages are used without diminishing positive clinical impact.
More Related Videos
Related Concept Videos
Pleural Effusion I: Introduction
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's...
Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
Behavior of Gas Molecules: Molecular Diffusion, Mean Free Path, and Effusion
Pleural Disorders: Types and Brief Description
Lung Capacity
Dose Size and Dosing Frequency: Determination Methods

